Notably, the FDA approved druggable targets for lung cancer, such as EGFR, MAP2K1, and MAP2K2, and proteins involved in the NSCLC pathway, including EGFR, NRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, CDK4, and TP53, were readily identified in DIA, whereas only TP53 and CDK1 were detected in DDA using our approach (Fig. 3e)34 (https://www.cancer.gov/about-cancer/treatment/drugs/lung). This evidence concerns the gene MAPK3 and lung cancer.